---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004974"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2026-07-29T11:00:20+00:00"
generated_at: "2026-07-29T11:06:14.905752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands

## Summary
- Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% YoY LC to >$1B; 2026 revenue outlook raised to ~$3.7B combined.
- Acquired Emalex for ~$700M cash; NDA for ecopipam (Tourette) submitted; $726M expenses in Q2.
- Generics revenues down 15% YoY LC due to lenalidomide competition; biosimilars on track for $800M by 2027.
- ADS program replaced with ordinary shares on NYSE starting Sept 14, 2026; Fitch upgraded to BBB-.

## SEC filing metadata
- accession: 0001171843-26-004974
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2026-07-29T11:00:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/0001171843-26-004974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/f8k_072926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004974
- JSON: https://secwatch.observer/filing/0001171843-26-004974.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.